- Home
- RIGL vs BWFG Comparison
RIGL vs BWFG Comparison
Compare RIGL & BWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- BWFG
- Stock Information
- Founded
- RIGL 1996
- BWFG 2002
- Country
- RIGL United States
- BWFG United States
- Employees
- RIGL N/A
- BWFG N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- BWFG Major Banks
- Sector
- RIGL Health Care
- BWFG Finance
- Exchange
- RIGL Nasdaq
- BWFG Nasdaq
- Market Cap
- RIGL 335.5M
- BWFG 273.2M
- IPO Year
- RIGL 2000
- BWFG N/A
- Fundamental
- Price
- RIGL $18.28
- BWFG $35.70
- Analyst Decision
- RIGL Buy
- BWFG Buy
- Analyst Count
- RIGL 5
- BWFG 1
- Target Price
- RIGL $36.40
- BWFG $42.00
- AVG Volume (30 Days)
- RIGL 170.2K
- BWFG 12.0K
- Earning Date
- RIGL 08-05-2025
- BWFG 07-23-2025
- Dividend Yield
- RIGL N/A
- BWFG 2.26%
- EPS Growth
- RIGL N/A
- BWFG N/A
- EPS
- RIGL 2.08
- BWFG 1.62
- Revenue
- RIGL $203,077,000.00
- BWFG $69,109,000.00
- Revenue This Year
- RIGL $14.41
- BWFG $59.47
- Revenue Next Year
- RIGL $15.97
- BWFG $13.75
- P/E Ratio
- RIGL $8.92
- BWFG $21.80
- Revenue Growth
- RIGL 70.16
- BWFG N/A
- 52 Week Low
- RIGL $7.48
- BWFG $22.80
- 52 Week High
- RIGL $29.82
- BWFG $36.00
- Technical
- Relative Strength Index (RSI)
- RIGL 37.91
- BWFG 58.76
- Support Level
- RIGL $18.35
- BWFG $33.85
- Resistance Level
- RIGL $19.21
- BWFG $35.97
- Average True Range (ATR)
- RIGL 0.89
- BWFG 0.69
- MACD
- RIGL -0.33
- BWFG -0.07
- Stochastic Oscillator
- RIGL 2.15
- BWFG 89.62
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About BWFG Bankwell Financial Group Inc.
Bankwell Financial Group Inc is a bank holding company, engaged in providing financial products and services. It offers products related to commercial lending, retail lending, depository services, and others. The bank's commercial lending products includes owner-occupied commercial real estate loans, commercial real estate investment loans, commercial loans to small and mid-sized businesses and real estate construction and development loans. The retail lending products include residential mortgage loans, home equity lines of credit, and consumer installment loans. Its depository products include checking, savings, money market, certificates of deposit, noninterest-bearing demand, and time deposits.